Skip to content

JBIO JBIO Operating Income

Operating Income at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.14B+80.6%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-$36.92M+13.5%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$125.13M-119%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$34.64M-25.8%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$53.7M+2.4%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$116.17M-23.8%

Other financials

Income statement

See full
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's operating income?
JBIO (JBIO) reported operating income of -$43.45M in Q1 2026.
How has JBIO's operating income changed year-over-year?
JBIO's operating income decreased by 85.8% year-over-year, from -$23.38M to -$43.45M.
What is the long-term trend for JBIO's operating income?
Over 4 years (2021 to 2025), JBIO's operating income has grown at a 49.0% compound annual growth rate (CAGR), from -$23.02M to -$113.54M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.